The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma

• Status: Recruiting
• Trial end date: 2025-05-25
• Target enrollment: 0
• Participant gender: All

Summary

The investigators want to assess the safety and efficacy of using intralesional 5-FU for the management of different types of BCC (including all the types EXCEPT the infiltrative one), by estimating different outcomes after the intralesional administration of 5-FU to BCC patient. Patients are randomly selected from the outpatient dermatologic clinic in the Aleppo University Hospital (AUH) over a period of 12 months and then these patients are followed up over another 12 months.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aleppo
• Collaborator: Aleppo University Hospital
• Treatments: Fluorouracil

Criteria

Inclusion Criteria:

• 5 Years to 90 Years (Child, Adult, Older Adult).

• Volunteer to participate in study

• Superficial lesion

• Nodular lesion (x ≤ 1.5 cm) patients are seen at the outpatient Department or in the dermatology wards at Aleppo University Hospital (AUH) over 12 months' period.

Exclusion Criteria:

• Ulcerative.

• Nodular lesion (x ≥ 1.5 cm)